Adrian L. Harris, MD, DPhil, is professor of medical oncology at the University of Oxford and director of the Cancer Research UK Medical Oncology Unit. He is a consultant medical oncologist at the National Health Service, Oxford Radcliffe Hospital Trust, a NIHR Comprehensive Biomedical Research Center designated by Cancer Research as one of three Comprehensive Cancer Centers.
Professor Harris's research is on tumor angiogenesis, hypoxia, and the metabolic response to hypoxia as key targets for anticancer therapy. He is interested in understanding the basic biology and science of disease, how this could be applied in development of new treatments and selecting the right patients for the right therapies. He has published over 1,000 papers in these areas.
He received his honors bachelor's degree in medicine and surgery in 1973 at Liverpool University, but undertook an intercalated biochemistry degree (first class honors) in 1969. He worked at Oxford University from 1975-1978, where he conducted research on mechanisms of resistance to anticancer drugs. He then took up a lectureship at the Royal Marsden Hospital where he developed an interest in the endocrine therapy of breast cancer with Professor Ian Smith, and helped develop early aromatase inhibitors.
In 1981, he was appointed professor of clinical oncology at the University of Newcastle Upon Tyne and in 1988 he was invited to Oxford to take up the foundation chair in medical oncology and lead the CRUK Molecular Oncology Laboratories at the Weatherall Institute of Molecular Medicine, one of the leading basic science institutes in the United Kingdom.